Latest Breaking News On - Endocrine cdk4 6 inhibitors - Page 1 : comparemela.com

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.

Stephanie graffTreatment approachBreast cancerRachel laymanEarly breast cancerHigh riskEndocrine cdk4 6 inhibitors